397 related articles for article (PubMed ID: 12050542)
1. Tachyphylaxis and phosphodiesterase type 5 inhibitors.
Steers WD
J Urol; 2002 Jul; 168(1):207. PubMed ID: 12050542
[No Abstract] [Full Text] [Related]
2. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
Carson CC
J Urol; 2002 Jul; 168(1):205. PubMed ID: 12073960
[No Abstract] [Full Text] [Related]
3. [Therapy of erectile dysfunction. Hard facts support sildenafil].
MMW Fortschr Med; 2003 Sep; 145(35-36):50-1. PubMed ID: 14584211
[No Abstract] [Full Text] [Related]
4. [Erectile dysfunction: an update on new therapeutic options].
Roumeguère T
Acta Urol Belg; 2000; 68(2):41-2. PubMed ID: 11098588
[No Abstract] [Full Text] [Related]
5. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
6. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
McCullough A
Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
[TBL] [Abstract][Full Text] [Related]
7. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
Katsarov M
Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
[No Abstract] [Full Text] [Related]
8. [Diagnosis of erectile dysfunction--what is still needed today?].
Weiske WH
Urologe A; 2003 Oct; 42(10):1317-21. PubMed ID: 14569379
[TBL] [Abstract][Full Text] [Related]
9. Oral drug treatment of erectile dysfunction.
Int J Impot Res; 2003 Dec; 15 Suppl 7():S27-9. PubMed ID: 14695970
[No Abstract] [Full Text] [Related]
10. [7 years PDE-5 inhibitor for therapy of erection disorders].
Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
[No Abstract] [Full Text] [Related]
11. [New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].
MMW Fortschr Med; 2003 Jun; 145(26):59. PubMed ID: 12916343
[No Abstract] [Full Text] [Related]
12. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
Mumtaz FH; Khan MA; Mikhailidis DP; Morgan RJ
J Urol; 2002 Jul; 168(1):206. PubMed ID: 12073962
[No Abstract] [Full Text] [Related]
13. Sildenafil and erectile dysfunction.
Fabbri A; Aversa A; Isidori A
J Endocrinol Invest; 1999 Jun; 22(6):486-92. PubMed ID: 10435861
[No Abstract] [Full Text] [Related]
14. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
Guay AT
J Urol; 2002 Jul; 168(1):205-6. PubMed ID: 12073961
[No Abstract] [Full Text] [Related]
15. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
Tomera K
J Urol; 2002 Jul; 168(1):206. PubMed ID: 12073963
[No Abstract] [Full Text] [Related]
16. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
17. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
Billups KL
J Urol; 2002 Jul; 168(1):204-5. PubMed ID: 12073959
[No Abstract] [Full Text] [Related]
18. Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?
Burnett AL
Urology; 2005 Feb; 65(2):224-30. PubMed ID: 15708027
[No Abstract] [Full Text] [Related]
19. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Watanabe H
Intern Med; 2004 Oct; 43(10):891-3. PubMed ID: 15575233
[No Abstract] [Full Text] [Related]
20. Sildenafil prescribed for erectile dysfunction may induce esophageal symptoms.
Kim BJ; Rhee PL; Son HJ
J Clin Gastroenterol; 2005 Aug; 39(7):643-4. PubMed ID: 16000937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
